SCHEMBL1224825

SCHEMBL1224825

O=C(Nc1ccccc1)n1nccc1/C=C/c1cccs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 9/20 0.48
▸ ALDH1A1 P00352 6/20 0.48
▸ SMN1; SMN2 Q16637 6/20 0.48
▸ NPC1 O15118 6/20 0.48
▸ MEN1 O00255 4/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ AURKA O14965 1/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ CDK2 P24941 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ HCAR2 Q8TDS4 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MAPT P10636 4/20 0.42
▸ GCK P35557 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ LMNA P02545 3/20 0.41
▸ TP53 P04637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1224827 1.00 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL1225516 0.90 SMN1; SMN2 (0.45) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL1225513 0.90 SMN1; SMN2 (0.45) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL2400810 0.83 SMN1; SMN2 (0.45) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL2400811 0.83 SMN1; SMN2 (0.45) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL1225646 0.75 LMNA (0.45) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL1225648 0.75 LMNA (0.45) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL2399767 0.72 F2 (0.48) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL1225817 0.72 RAB9A (0.48) RAB9AALDH1A1SMN1; SMN2NPC1MEN1
SCHEMBL2399771 0.72 F2 (0.48) RAB9AALDH1A1SMN1; SMN2NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-09-22 — — US claimed
US-8193177-B2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases ANGION BIOMEDICA CORP. (US) 2012-06-05 — — US disclosed
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2011-09-22 — — US disclosed
US-7879898-B1 treating a chronic obstructive pulmonary disease using modulators of HGF/SF activity; for example, 3-(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)-1-(4-chlorophenyl)prop-2-en-1-one; emphysema ANGION BIOMEDICA CORP. (US) 2011-02-01 — — US disclosed
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES ANGION BIOMEDICA CORP. 2010-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230407-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA HGF, HGFAC, HDGF RAB9A 3894/4885ALDH1A1 3300/4885SMN1; SMN2 112/4885
US-20100256117-A1 HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES HGF, HDGF, HGFAC RAB9A 3231/4885ALDH1A1 1992/4885SMN1; SMN2 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback